Study of dovramilast for leprosy type 2 reaction
Treatments studied
Part of Immune system & allergy, Infections, Skin clinical trials.
This study tests a new medicine called dovramilast to see if it can help people with leprosy type 2 reaction, a painful skin condition. It compares the new medicine to the standard treatment to find out if it works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have had leprosy in the past or currently have it.
- You must have at least 10 tender skin bumps or nodules from leprosy type 2 reaction.
- You must not have taken certain medicines for leprosy type 2 reaction in the last 28 days.
- You must not have other serious infections or health conditions that are not controlled.
- You must agree to use reliable birth control if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at new ways to diagnose and treat leprosy. It includes patients with a more serious form of leprosy and the people who live closely with them, to help stop the spread of the disease.
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
This study looks at whether a specific gene (Rab 32) affects how leprosy progresses. It may help doctors better predict outcomes for people with leprosy.
This study tests two new oral medicines (called LXE408) against an existing oral treatment (miltefosine) for people with a first episode of localized cutaneous leishmaniasis (skin sores caused by a parasite). The goal is to see if the new medicines are safe and work better at healing the sores.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This Phase 2 trial tests whether adding metformin to standard leprosy treatment (multidrug therapy, or MDT) helps people with multibacillary leprosy recover better and remain tolerable over 48 weeks. Participants also get monitored closely for side effects and safety issues.
Hear when a new Erythema Nodosum Leprosum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.